ALMS - Alumis Inc

https://www.alumis.com

Buy Momentum: Bearish

Recent News

Alumis to Participate in Upcoming September Investor Conferences - Alumis ( NASDAQ:ALMS )

Benzinga • 2 weeks, 3 days ago • score: 0.21

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ALMS, a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:

Neutral

Alumis to Participate in Upcoming September Investor Conferences

GlobeNewswire • 2 weeks, 3 days ago • score: 0.12

Alumis management will participate in several healthcare conference upcoming in September ...

Bullish

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

GlobeNewswire • 1 month, 3 weeks ago • score: 0.19

Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in ...

Bullish

Alumis to Present at the Jefferies Global Healthcare Investor Conference - Alumis ( NASDAQ:ALMS )

Benzinga • 3 months, 2 weeks ago • score: 0.18

SOUTH SAN FRANCISCO, Calif., May 29, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ALMS, a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will ...

Bullish

Alumis to Present at the Jefferies Global Healthcare Investor Conference

GlobeNewswire • 3 months, 2 weeks ago • score: 0.19

Alumis to present at Jefferies Global Healthcare Conference on June ...

Bullish

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

GlobeNewswire • 3 months, 2 weeks ago • score: 0.26

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis ...

Bullish

Alumis Completes Merger with ACELYRIN - Alumis ( NASDAQ:ALMS )

Benzinga • 3 months, 3 weeks ago • score: 0.29

SOUTH SAN FRANCISCO, Calif., May 21, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ALMS, a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc.

Bullish

Alumis Completes Merger with ACELYRIN

GlobeNewswire • 3 months, 3 weeks ago • score: 0.30

Alumis Completes Merger with ...

Bullish

Alumis Stockholders Approve Merger with ACELYRIN

GlobeNewswire • 4 months ago • score: 0.23

Alumis Stockholders Approve Merger with ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$13.11

52W Low

$2.76

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

0.14

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

1.09

P/S (TTM) (<3 favorable)

23.40

P/B (<3 favorable)

0.97

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.83%

Institutions (25–75% balanced)

81.07%

Shares Outstanding

96,879,000

Float

71,050,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

20,055,000

Gross Profit (TTM)

20,055,000

EPS (TTM)

33.18

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-45.33%

ROE (TTM) (>15% strong)

-0.66%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0156

0.0278

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025